Format

Send to

Choose Destination
J Hum Virol. 2001 Jan-Feb;4(1):1-7.

The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.

Author information

1
Division of Clinical Virology, Karolinska Institutet, Stockholm, Sweden.

Abstract

OBJECTIVE:

To determine whether short peptides corresponding to the RGPGR motif of the V3 loop of gp 120 have anti-human immunodeficiency virus type 1 (anti-HIV-1) activity.

DESIGN/METHODS:

Short peptides were tested against the HIV-1 laboratory strains and clinical isolates.

RESULTS:

The tripeptide glycyl-prolyl-glycine amide (GPG-NH2) inhibited the replication of both laboratory strains and 47 clinical isolates, including 19 strains that were resistant to other drugs or that were from patients with failing therapy. The 50% inhibitory concentrations values were 2.7 to 37 microM. Phenotypic change of two isolates from nonsyncytia-inducing to syncytia-inducing did not change their sensitivity to GPG-NH2. The tripeptide added to the antiviral effect of both zidovudine and ritonavir.

CONCLUSIONS:

The tripeptide GPG-NH2 is a nontoxic compound that inhibits the replication of HIV-1 by an apparently new mode of action. Glycyl-prolyl-glycine-NH2 might prove useful by itself or as a lead compound for the treatment of drug-resistant HIV-1. Glycyl-prolyl-glycine-NH2 is currently undergoing phase I/II human clinical trials in Sweden.

PMID:
11213928
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center